AAAAAA
Results:
1-13
|
Results: 13
Authors:
ORLANDI C
QUINN JB
ISKANDRIAN AE
VERANI MS
DIXON M
HELLER GV
TAILLEFER R
Citation: C. Orlandi et al., PREDICTION OF OUTCOME AFTER CORONARY REVASCULARIZATION IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION - THE I-123 IPPA VIABILITY MULTICENTERSTUDY, Journal of the American College of Cardiology, 31(2), 1998, pp. 260-260
Authors:
QUINN JB
Citation: Jb. Quinn, THE INDIVIDUALIZED CORPORATION - GHOSHAL,S, BARTLETT,CA, Sloan management review, 39(2), 1998, pp. 97-98
Authors:
NEW DL
QUINN JB
QURESHI MZ
SIGLER SJ
Citation: Dl. New et al., VERTICALLY TRANSMITTED BABESIOSIS, The Journal of pediatrics, 131(1), 1997, pp. 163-164
Authors:
QUINN JB
QUINN GD
Citation: Jb. Quinn et Gd. Quinn, INDENTATION BRITTLENESS OF CERAMICS - A FRESH APPROACH, Journal of Materials Science, 32(16), 1997, pp. 4331-4346
Authors:
KURITZKES DR
QUINN JB
BENOIT SL
SHUGARTS DL
GRIFFIN A
BAKHTIARI M
POTICHA D
ERON JJ
FALLON MA
RUBIN M
Citation: Dr. Kuritzkes et al., DRUG-RESISTANCE AND VIROLOGICAL RESPONSE IN NUCA-3001, A RANDOMIZED TRIAL OF LAMIVUDINE (3TC) VERSUS ZIDOVUDINE (ZDV) VERSUS ZDV PLUS 3TC IN PREVIOUSLY UNTREATED PATIENTS, AIDS, 10(9), 1996, pp. 975-981
Authors:
QUINN JB
BARUCH JJ
ZIEN KA
Citation: Jb. Quinn et al., SOFTWARE-BASED INNOVATION, Sloan management review, 37(4), 1996, pp. 11-24
Authors:
QUINN JB
ANDERSON P
FINKELSTEIN S
Citation: Jb. Quinn et al., MANAGING PROFESSIONAL INTELLECT - MAKING THE MOST OF THE BEST, Harvard business review, 74(2), 1996, pp. 71
Authors:
BARTLETT JA
BENOIT SL
JOHNSON VA
QUINN JB
SEPULVEDA GE
EHMANN WC
TSOUKAS C
FALLON MA
SELF PL
RUBIN M
Citation: Ja. Bartlett et al., LAMIVUDINE PLUS ZIDOVUDINE COMPARED WITH ZALCITABINE PLUS ZIDOVUDINE IN PATIENTS WITH HIV-INFECTION, Annals of internal medicine, 125(3), 1996, pp. 161
Authors:
JOHNSON VA
WAGNER SF
OVERBAY CB
WAGNER JR
CAMMACK N
PENN CR
RUBIN M
BARTLETT JA
FALLON MA
QUINN JB
BENOIT SL
Citation: Va. Johnson et al., DRUG-RESISTANCE AND VIRAL LOAD IN NUCA-3002 - A COMPARATIVE TRIAL OF LAMIVUDINE (3TC) (HIGH OR LOW DOSE) ZIDOVUDINE (ZDV) COMBINATION THERAPY VS ZDV/DIDEOXYCYTIDINE (DDC) COMBINATION THERAPY IN ZDV-EXPERIENCED(GREATER-THAN-OR-EQUAL-TO-24 WEEKS) PATIENTS (CD4 CELLS 100-300/MM(3))/, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 55-55
Authors:
ERON JJ
BENOIT SL
JEMSEK J
MACARTHUR RD
SANTANA J
QUINN JB
KURITZKES DR
FALLON MA
RUBIN M
Citation: Jj. Eron et al., TREATMENT WITH LAMIVUDINE, ZIDOVUDINE, OR BOTH IN HIV-POSITIVE PATIENTS WITH 200 TO 500 CD4+ CELLS PER CUBIC MILLIMETER, The New England journal of medicine, 333(25), 1995, pp. 1662-1669
Authors:
PLUDA JM
COOLEY TP
MONTANER JSG
SHAY LE
REINHALTER NE
WARTHAN SN
RUEDY J
HIRST HM
VICARY CA
QUINN JB
YUEN GJ
WAINBERG MA
RUBIN M
YARCHOAN R
Citation: Jm. Pluda et al., A PHASE I II STUDY OF 2'-DEOXY-3'-THIACYTIDINE (LAMIVUDINE) IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION/, The Journal of infectious diseases, 171(6), 1995, pp. 1438-1447
Authors:
QUINN JB
HILMER FG
Citation: Jb. Quinn et Fg. Hilmer, STRATEGIC OUTSOURCING, Sloan management review, 35(4), 1994, pp. 43-55
Authors:
QUINN JB
BUCHANAN J
BUCHANAN W
Citation: Jb. Quinn et al., THE PRODUCT FAMILY, Sloan management review, 34(4), 1993, pp. 5-5
Risultati:
1-13
|